2353 results
Article
People, partnerships and pathways – improving breast cancer services in Northern Ireland
Over the last year, we’ve been trying to better understand breast cancer in Northern Ireland. We’ve engaged with people affected by breast cancer, local politicians, cancer charities, healthcare professionals and representatives from the Department of Health and Public Health Agency.
Our research unit
The Breast Cancer Now Research Unit at King's College London is entirely focused on studying triple negative breast cancer. Find out more.
Event
Dorney Triathlon
You get to race around this inspiring Olympic venue in the Dorney Triathlon. Known for being a flat course, this is your chance to achieve that personal best.
Article
We respond to Scottish Medicines Consortium decision to approve ribociclib and reject elacestrant for use on NHS in Scotland
Claire Rowney, chief executive at Breast Cancer Now, said:
Healthcare Information
Wigs, scarves and headwear
Read more about wigs, headscarves, hats and other headwear you may want to wear after hair loss.
Article
The National Cancer Patient Experience Survey
Every year, The National Cancer Patient Experience Survey goes out. This is what you need to know about it.
Article
Caring for scars after breast cancer surgery
Scars are a natural part of the body's healing process but they can cause irritation and some find them unsightly. Here, we talk about caring for scars after breast cancer surgery.
Drug
Trastuzumab emtansine (Kadcyla)
Learn how certain types of breast cancer can be treated with trastuzumab emtansine, also known by its brand name, Kadcyla. Find out who it’s for and the possible side effects.
Article
We respond to new figures from Cancer Research UK showing thousands fewer breast cancer patients started treatment in the last year in England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
Article
We respond to the latest COVID-19 guidance
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:
Article
A potential new way to overcome fulvestrant resistance in secondary breast cancer
Scientists have furthered our understanding of how some secondary breast cancers can become resistant to the hormone therapy fulvestrant.
Drug
Leuprorelin (Prostap)
Leuprorelin, also known as Prostap, is a hormone therapy used to treat breast cancer in women who've not been through the menopause.